Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Mifepristone: Interim Phase I/II data

    Corcept Therapeutics Inc. (NASDAQ:CORT), Menlo Park, Calif. Product: Mifepristone (Corluxin, Korlym) (formerly Corlux) Business: Cancer Molecular target: Progesterone receptor; Cortisol receptor GR-2 Description: …

    Published on 6/29/2015
  • PF-05280602: Phase I data

    Catalyst Biosciences Inc., South San Francisco, Calif. Product: PF-05280602 (formerly CB 813d) Business: Hematology Molecular target: Factor VIIa Description: Second-generation variant of human coagulation Factor VIIa …

    Published on 6/29/2015
  • PRN1008: Phase I data

    Principia Biopharma Inc., South San Francisco, Calif. Product: PRN1008 Business: Autoimmune Molecular target: Brutons tyrosine kinase (Btk) Description: Oral reversible covalent Brutons tyrosine kinase (Btk) inhibitor …

    Published on 6/29/2015
  • Rociletinib: Additional Phase I/II data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Product: Rociletinib (AVL-301) (formerly CO-1686) Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) …

    Published on 6/29/2015
  • RPL554: Additional Phase I/II data

    Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc (LSE:VRP), London, U.K. Product: RPL554 Business: Pulmonary Molecular target: Phosphodiesterase-3 (PDE-3); Phosphodiesterase-4 (PDE-4) Description: Nebulized dual…

    Published on 6/29/2015
  • Rucaparib: Updated Phase II data

    Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Pfizer Inc. (NYSE:PFE), New York, N.Y. Cancer Research UK, London, U.K. Product: Rucaparib (CO-338) (formerly PF-01367338, AG-014699) Business: Cancer Molecular target:…

    Published on 6/29/2015
  • Scyllo-inositol: Phase II/III data

    Transition Therapeutics Inc. (TSX:TTH; NASDAQ:TTHI), Toronto, Ontario Product: Scyllo-inositol (AZD-103, ELND005) Business: Neurology Molecular target: Beta amyloid Description: Small molecule that disaggregates beta …

    Published on 6/29/2015
  • Tazemetostat: Additional Phase I/II data

    Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Tazemetostat (E7438, EPZ-6438) Business: Cancer Molecular target: Enhancer of zeste homolog 2 (EZH2) Description: Selective…

    Published on 6/29/2015
  • Tremelimumab: Additional Phase Ib data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Tremelimumab (CP-675,206, CP-675206, CP-675) Business: Cancer Molecular target: CTLA-4 (CD152) Description: Human mAb …

    Published on 6/29/2015
  • VB-111: Phase I/IIa data

    VBL Therapeutics Ltd. (NASDAQ:VBLT), Or Yehuda, Israel Product: VB-111 Business: Cancer Molecular target: NA Description: Anti-angiogenic therapy consisting of a non-replicating adenovirus vector with a modified murine …

    Published on 6/29/2015
  • VB-111: Updated Phase II data

    VBL Therapeutics Ltd. (NASDAQ:VBLT), Or Yehuda, Israel Product: VB-111 Business: Cancer Molecular target: NA Description: Anti-angiogenic therapy consisting of a non-replicating adenovirus vector with a modified murine …

    Published on 6/29/2015
  • Velusetrag: Phase II data

    Alfa Wassermann S.p.A., Bologna, Italy Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Product: Velusetrag (TD-5108) Business: Gastrointestinal Molecular target: Serotonin (5-HT4) receptor …

    Published on 6/29/2015
  • Vigil vaccine: Phase I data

    Gradalis Inc., Dallas, Texas Product: Vigil vaccine (formerly FANG vaccine) Business: Cancer Molecular target: Transforming growth factor (TGF) beta 1 (TGFB1); Transforming growth factor (TGF) beta 2 (TGFB2) Description…

    Published on 6/29/2015
  • Abaloparatide-SC: Extension study data

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Radius Health Inc. (NASDAQ:RDUS), Cambridge, Mass. Teijin Pharma Ltd., Tokyo, Japan Product: Abaloparatide-SC (BA058-SC) (formerly BA058 Injection) …

    Published on 6/22/2015
  • Actimab-A: Additional Phase I/II data

    Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y. Product: Actimab-A Business: Cancer Molecular target: CD33 Description: Actinium-225 attached to the anti-CD33 mAb lintuzumab (HuM195) Indication: Treat acute …

    Published on 6/22/2015
  • Alimta pemetrexed: Phase III final data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Alimta pemetrexed Business: Cancer Molecular target: Dihydrofolate reductase (DHFR); Glycinamide ribonucleotide formyltransferase (GARFT) Description: Antifolate…

    Published on 6/22/2015
  • Anagrelide CR: Updated Phase II data

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: Anagrelide CR (GALE-401) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide Indication: Treat …

    Published on 6/22/2015
  • ARGX-111: Phase Ib data

    arGEN-X N.V. (Euronext:ARGX), Breda, the Netherlands Product: ARGX-111 Business: Cancer Molecular target: c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) Description: C-Met receptor tyrosine …

    Published on 6/22/2015
  • Arzerra ofatumumab: Additional Phase III data

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Arzerra ofatumumab (HuMax-CD20) Business: Cancer Molecular target: CD20 Description: Human mAb against…

    Published on 6/22/2015
  • Arzerra ofatumumab: Phase III data

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Arzerra ofatumumab (HuMax-CD20) Business: Cancer Molecular target: CD20 Description: Human mAb against…

    Published on 6/22/2015
  • AVA-101: Phase IIa data

    Avalanche Biotechnologies Inc. (NASDAQ:AAVL), Menlo Park, Calif. Product: AVA-101 Business: Ophthalmic Molecular target: Vascular endothelial growth factor (VEGF) Description: Adeno-associated virus (AAV) vector-based …

    Published on 6/22/2015
  • Belinostat: Additional Phase I/II data

    Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Product: Belinostat (Beleodaq) (IV PXD101) Business: Cancer Molecular target: Histone deacetylase (HDAC)…

    Published on 6/22/2015
  • CAT-2054: Preliminary Phase I data

    Catabasis Pharmaceuticals Inc., Cambridge, Mass. Product: CAT-2054 Business: Endocrine/Metabolic Molecular target: NA Description: Conjugate of niacin and eicosapentaenoic acid (EPA) covalently linked using SMART linker…

    Published on 6/22/2015
  • CTL019: Phase IIa data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland University of Pennsylvania, Philadelphia, Pa. Product: CTL019 (formerly CART-19) Business: Cancer Molecular target: CD19 Description: Autologous T cells loaded with a…

    Published on 6/22/2015
  • Cyramza ramucirumab: Phase II data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Cyramza ramucirumab (LY3009806, IMC-1121B) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) …

    Published on 6/22/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993